Reaction

Acquired Gene Mutation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,303 reports · 60 co-occurring drugs

As of the last recalculation, Acquired Gene Mutation appears in 1,303 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 569.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gefitinib	258	569.0	585.9
Osimertinib	473	369.5	375.0
Lamivudine Oral	142	100.5	101.1
Erlotinib	56	96.4	97.0
Nevirapine	50	92.0	92.5
Erlotinib Hydrochloride	65	87.3	87.7
Lamivudine	142	82.3	82.6
Pemetrexed	86	68.5	68.8
Tenofovir Disoproxil Fumarate Tablets	35	66.5	66.8
Zidovudine	45	55.6	55.8
Vincristine Sulfate	92	53.9	54.1
Crizotinib	40	51.8	52.0
Doxorubicin Hydrochloride	89	46.7	46.8
Imatinib	49	46.1	46.2
Pemetrexed Disodium	95	42.9	43.0
Tenofovir Disoproxil Fumarate	73	37.3	37.4
Olaparib	40	31.5	31.5
Doxorubicin	144	28.9	28.9
Bosutinib	13	23.3	23.4
Temozolomide	27	20.9	20.9
Acalabrutinib	13	17.3	17.3
Dasatinib	38	16.8	16.8
Darunavir	15	16.0	16.0
Fulvestrant	31	15.3	15.3
Cisplatin	71	15.3	15.3
Efavirenz	10	14.4	14.4
Gemcitabine Hydrochloride	46	14.3	14.3
Trametinib	21	14.1	14.1
Carboplatin	103	14.0	14.0
Dabrafenib	18	13.8	13.8
Ritonavir 100 Mg	12	12.9	13.0
Vismodegib	7	12.6	12.6
Prednisolone	127	12.3	12.4
Prednisolone Oral	127	12.3	12.4
Prednisolone Oral Solution	127	12.3	12.4
Nilotinib	22	12.1	12.1
Bleomycin Sulfate	7	10.9	10.9
Goserelin	9	10.8	10.8
Blinatumomab	7	10.8	10.8
Cyclophosphamide Injection, Solution	110	10.7	10.8
Cyclophosphamide	110	10.7	10.8
Cyclophosphamide For Injection	110	10.7	10.8
Anastrozole Tablets	14	10.5	10.5
Etoposide	45	10.1	10.1
Tretinoin	5	9.9	9.9
Bicalutamide	9	9.5	9.5
Bevacizumab	70	9.5	9.5
Ritonavir	17	9.4	9.4
Paclitaxel (Aibumin-Bound)	43	8.6	8.6
Pembrolizumab	50	7.9	7.9
Gemcitabine	19	7.8	7.8
Ifosfamide	10	7.5	7.5
Paclitaxel	45	7.5	7.5
Panitumumab	7	7.2	7.2
Durvalumab	9	7.1	7.1
Abiraterone	5	5.9	5.9
Alpelisib	3	5.5	5.5
Docetaxel Anhydrous	22	5.3	5.3
Docetaxel	22	5.3	5.3
Cabozantinib	15	5.0	5.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.